archive-ca.com » CA » H » HEMOPHILIA.CA

Total: 850

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CHS Research Grants for 2009 - Canadian Hemophilia Society
    CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships ended recently Canadian Hemophilia Society International Projects Fund Canadian Organizational Twins Recently closed twinning partnerships Treatment Centres British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Prince Edward Island Nova Scotia Newfoundland and Labrador HCV HIV Hepatitis C and HIV Compensation I am a survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick Chapter Commemoration 2012 Hemophilia Ontario Commemoration 2012 Hemophilia Saskatchewan Commemoration 2012 Hemophilia Saskatchewan Commemoration 2103 Hemophilia Ontario Commemoration 2013 Hemophilia Alberta Commemoration 2014 Media Room Press releases 2009 2011 Press releases 2006 2008 Search Français Our Partners CHS Research Grants for 2009 The role of X inactivation in the expression of hemophilia A in women An evaluation of the prevalence and functional significance of non neutralizing antibodies to factor VIII Phenotypic Characterization of Three Candidate Type 2B von Willebrand Disease Missense Mutants Use of amphipathic helical peptides coupled to nanofibrous microspheres to control hemorrhagic external bleeding in hemophiliacs Risk of Ischemic Heart Disease in Hemophilia Evaluating Endothelial Function and the Development of Atherosclerotic Vascular Disease in Hemophilia Use of Ports in Canadian Hemophilia Prophylaxis Study CHPS The role of X inactivation in the expression of hemophilia A in women Dr Wenda L Greer FCCMG Professor Department of Pathology Dalhousie University Halifax Nova Scotia Second year funding Co investigators Dr Sue Robinson Dr Sarah Dyack Hemophilia A HA is an X linked bleeding disorder resulting from mutations in the F8 gene One functional F8 gene is sufficient for normal clotting Thus typically XY males who interit one mutated F8 gene are affected while heterozygous XX females are not Rarely heterozygous females with HA have been described These can arise due to unfavourably skewed X chromosome inactivation XCI This is a dosage compensation mechanism that causes one X in every female cell to be inactivated early in development In most females approximately half of their cells inactivate their maternal and half their paternal X In rare cases XCI is skewed If it is skewed toward the activation of a mutated gene a heterozygous female can be affected A family has presented with several males and several females affected with HA In the females most cells were expressing the mutated paternal X chromosome It is unlikely that chance could account for the dramatic skewing of XCI leading to 3 affected females Our objective is to understand why these females are expressing HA Our hypothesis is that is is due to skewed XCIR resulting from an inherited predisposition for the mutated X chromosome to remain active Our aims are to determine XCI patterns and correlate these with disease expression determine whether XCIR skewing is more consistent with genetically influenced or random XCI delineate through microsatellite analysis a region of the X chromosome that is associated with varied susceptibility of XCI consider potential candidate genes from this region identify the clinical symptoms and standards of care of carrier females and their experiences with medical treatment by interviewing carrier females and healthcare professionals We believe that this family provides a unique opportunity to study XCI and its role in the expression of HA in heterozygous females It also provides an opportunity to document the clinical phenotype of female carriers who differ in their factor VIII activities according to their respective XCIR This project was extended until August 31 2011 An evaluation of the prevalence and functional significance of non neutralizing antibodies to factor VIII Dr David Lillicrap Department of Pathology and Molecular Medicine Queen s University Kingston Ontario Second year funding Co investigators Dr Jerome Teitel Dr Georges Étienne Rivard Dr Irwin Walker Funded through an unrestricted research grant to the Canadian Hemophilia Society from Bayer HealthCare The development of antibodies to factor VIII FVIII represents the main treatment related complication of current therapies for hemophilia A For the past 30 years this complication has been evaluated by a laboratory test that detects only those antibodies that interfere with FVIII s

    Original URL path: http://www.hemophilia.ca/en/research/chs-dream-of-a-cure-research-program/chs-research-grants-for-2009/ (2014-10-09)
    Open archived version from archive


  • CHS Research Grants for 2008 - Canadian Hemophilia Society
    C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick Chapter Commemoration 2012 Hemophilia Ontario Commemoration 2012 Hemophilia Saskatchewan Commemoration 2012 Hemophilia Saskatchewan Commemoration 2103 Hemophilia Ontario Commemoration 2013 Hemophilia Alberta Commemoration 2014 Media Room Press releases 2009 2011 Press releases 2006 2008 Search Français Our Partners CHS Research Grants for 2008 Platelet type von Willebrand disease An underdiagnosed cause of excessive mucocutaneous bleeding Factor VII a clearance behaviour Structural and genetic analysis of the complexes between factor VIII and low density lipoprotein receptor related protein Toward a long acting factor VIII The role of X inactivation in the expression of hemophilia A in women An evaluation of the prevalence and functional significance of non neutralizing antibodies to factor VIII Carrier frequency among mothers of children with hemophilia Transfusions and regional anesthesia of the knee Platelet type von Willebrand disease An underdiagnosed cause of excessive mucocutaneous bleeding Dr Maha Othman Adjunct Assistant Professor Department of Pathology and Molecular Medicine Queen s University Kingston Ontario Second year funding Co investigator Dr David Lillicrap Platelet type von Willebrand disease PT VWD and type 2B von Willebrand disease have similar clinical as well as laboratory features while resulting from abnormalities in two different genes Type 2B VWD results from a defective von Willebrand factor VWF and PT VWD is caused by platelet GP1BA gene defect The discrimination between the two disorders is often a challenge The general tests necessary for the identification require particular technical experience and necessitate fresh blood samples Definitive diagnoses can be made by revealing the gene defect in either the VWF or the GP1BA The correct diagnosis and discrimination between the two disorders has important implication on treatment decision The VWF FVIII concentrate the major treatment in type 2B VWD may worsen platelet count and bleeding conditions in PT VWD Platelet concentrate is the ideal treatment for PT VWD In this study we propose that patients with PT VWD are being under miss diagnosed among type 2B VWD and we adopt the use of a genetic approach for a definitive diagnosis of PT VWD The DNA analysis will include the related area of the VWF gene responsible for type 2B VWD and also the platelet GP1BA gene responsible for PT VWD in 100 patients initially diagnosed with type 2B VWD from Canada and worldwide Under the auspices of the International Society for Thrombosis and Hemostasis Scientific and Standardization Committee on von Willebrand Factor we established an online database disease registry now accessible at www pt vwd org The project registry will address the question of how many PT VWD cases are being misdiagnosed among the type 2B VWD cases increase awareness among physicians specialists and patients about this diagnostic problem and will indicate the significance of the genetic analysis in these patients with subsequent implication on treatment decision Factor VII a clearance behaviour Dr William P Sheffield Associate Professor Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario Second year funding Co investigator Dr B J Clarke The hemophilia community knows all too well that the replacement therapy that can restore hemophiliacs to an active life is not always problem free For individuals with hemophilia A replacement therapy with purified recombinant factor VIII fVIII can sometimes be complicated by inhibitor formation Inhibitors are antibodies directed against the injected fVIII Fortunately administration of recombinant factor VIIa fVIIa can bypass this potentially serious problem However fVII is one of the coagulation factors that leaves the circulation the most rapidly This clearance behaviour is not completely understood For this reason Drs Bill Sheffield and Bryan Clarke of McMaster University and Canadian Blood Services have received a CHS research grant to study the clearance of fVII a in mice genetically altered to have hemophilia A The investigators will use DNA and cell culture technology to make both human fVII identical to current clinical products and new forms of fVII in their laboratories Once purified how long the fVII related proteins last in the mouse circulation and how well they control bleeding will be determined The most unusual products to be tested are fusions in which fVII and human serum albumin ordinarily separate proteins are combined into a single chain The researchers propose that fVII will continue to work in this new format and will remain in the circulation for much longer than the current product The longer it remains the more effective it should be in combating bleeding Sheffield and Clarke hope that their research will lead to better understanding of the mechanism of action of rfVIIa and to the design of improved rfVII a products to provide caregivers with novel tools to help hemophiliac patients with inhibitors Structural and genetic analysis of the complexes between factor VIII and low density lipoprotein receptor related protein Toward a long acting factor VIII Ann English PhD Department of Chemistry and Biochemistry Concordia University Montreal Quebec First year funding Co investigator Dr Tongpil Min CO PI Scientific developments have provided a new generation of safer factor VIII FVIII biopharmaceuticals that are free of blood born pathogens However the high cost of FVIII still remains a big hurdle in hemophilia treatment Only certain countries can afford prophylaxis or on demand treatment while many others cannot even meet on demand requirements Clearly FVIII has to be further developed to yield a product with a prolonged half life Our project that is being supported by the

    Original URL path: http://www.hemophilia.ca/en/research/chs-dream-of-a-cure-research-program/chs-research-grants-for-2008/ (2014-10-09)
    Open archived version from archive

  • CHS Research Grants for 2007 - Canadian Hemophilia Society
    on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships ended recently Canadian Hemophilia Society International Projects Fund Canadian Organizational Twins Recently closed twinning partnerships Treatment Centres British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Prince Edward Island Nova Scotia Newfoundland and Labrador HCV HIV Hepatitis C and HIV Compensation I am a survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick Chapter Commemoration 2012 Hemophilia Ontario Commemoration 2012 Hemophilia Saskatchewan Commemoration 2012 Hemophilia Saskatchewan Commemoration 2103 Hemophilia Ontario Commemoration 2013 Hemophilia Alberta Commemoration 2014 Media Room Press releases 2009 2011 Press releases 2006 2008 Search Français Our Partners CHS Research Grants for 2007 The role of X inactivation in the expression of hemophilia A in women Gene therapy of hemophilia A Platelet type von Willebrand disease An underdiagnosed cause of excessive mucocutaneous bleeding Factor VII a clearance behaviour The role of X inactivation in the expression of hemophilia A in women Dr Wenda L Greer FCCMG Professor Department of Pathology Dalhousie University Halifax Nova Scotia Second year funding Hemophilia A is an X linked recessive bleeding disorder resulting from mutations in the F8 gene It is usually expressed in males who inherit only one X chromosome from their mother Females inherit one X from each parent Those who inherit only one mutated f8 gene usually do not express the disease Rare examples of hemophilia A manifesting in heterozygous females occur due to an unusual pattern of X chromosome inactivation This is a mechanism that causes one X in every female cell to be inactivated early in development It is a mechanism which compensates for the fact that females have a double dose of X chromatin compared to males In most females approximately half of the cells inactivate their maternal X and half their paternal X In rare cases X chromosome inactivation is skewed If it is skewed toward the expression of a mutated X chromosome a heterozygous female can be affected with an X linked recessive disease A family has presented with several males and several females affected with hemophilia A Analysis of one female showed that most of her cells were expressing the mutated paternal X chromosome We therefore hypothesized that affected females in this family are expressing hemophilia A due to nonrandom X inactivation patterns It is unlikely that random chance could account for the putative dramatic skewing of X chromosome inactivation leading to 3 affected females This led us to consider that these females have inherited a predisposition to skewed X chromosome inactivation patterns XCI is controlled in cis by an untranslated RNA coded by the XIST gene Xist is regulated by the Tsix RNA that is antisense to Xist It is believed from studies in mice that there is an X chromosome controlling element XCE that down regulates Tsix expression and alters the probability of an X chromosome being inactivated Our objective is to understand why females in this family are expressing hemophilia A Our hypothesis is that their X chromosomes containing the normal F8 gene have been selectively inactivated leaving only the mutated f8 available for expression More specifically we propose to test the hypothesis that there is a region

    Original URL path: http://www.hemophilia.ca/en/research/chs-dream-of-a-cure-research-program/chs-research-grants-for-2007/ (2014-10-09)
    Open archived version from archive



  • CHS Research Grants for 2006 - Canadian Hemophilia Society
    Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships ended recently Canadian Hemophilia Society International Projects Fund Canadian Organizational Twins Recently closed twinning partnerships Treatment Centres British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Prince Edward Island Nova Scotia Newfoundland and Labrador HCV HIV Hepatitis C and HIV Compensation I am a survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick Chapter Commemoration 2012 Hemophilia Ontario Commemoration 2012 Hemophilia Saskatchewan Commemoration 2012 Hemophilia Saskatchewan Commemoration 2103 Hemophilia Ontario Commemoration 2013 Hemophilia Alberta Commemoration 2014 Media Room Press releases 2009 2011 Press releases 2006 2008 Search Français Our Partners CHS Research Grants for 2006 The Role of X inactivation in the Expression of Hemophilia A in Women Genetic Differences Between Obligate Carriers of Type 3 VWD and Individuals with Type 1 VWD Implantable Microcapsules as Gene Therapy for Hemophilia A The Role of X inactivation in the Expression of Hemophilia A in Women

    Original URL path: http://www.hemophilia.ca/en/research/chs-dream-of-a-cure-research-program/chs-research-grants-for-2006/ (2014-10-09)
    Open archived version from archive

  • CHS Research Grants for 2005 - Canadian Hemophilia Society
    being Destination fitness Home care The road to independence Roadmap for managing pain Navigating the emergency department Bon Voyage Travelling with a bleeding disorder Charting Your Course PEP Parents Empowering Parents program Vocational assessment tool Career planning and scholarship links Scholarship Program Federal and Provincial Support Programs Insurance coverage Educational Material Printed documents Bleeding disorders in women Carriers of hemophilia A or B Hemophilia Hepatitis C HIV Inhibitors Physical activity and sports Platelet function disorders Rare factor deficiencies Relevant to all bleeding disorders Resources for children Von Willebrand disease Videos Care and Treatment Emergency Care Pain Management Nursing Physiotherapy Introduction Constitution of the Canadian Physiotherapists in Hemophilia Care CPHC Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment Centre partnerships

    Original URL path: http://www.hemophilia.ca/en/research/chs-dream-of-a-cure-research-program/chs-research-grants-for-2005/ (2014-10-09)
    Open archived version from archive

  • The CHS / Pfizer Care Until Cure Research Program - Canadian Hemophilia Society
    deficiency Summary Chart Platelet function disorders Introduction Symptoms of platelet function disorders Diagnosis of platelet function disorders Types of platelet function disorders Treatment of platelet function disorders Precautions PDF documents Clotting factor concentrates Women Inherited bleeding disorders affecting women Symptoms Diagnosis Inheritance Medical treatment options for menorrhagia and other symptoms Gynaecological treatment options for menorrhagia Precautions for pregnant women Staying healthy Bleeding disorder treatment centres Educational resources Stories from women and girls who bleed too much About the CHS Support and Education Passport to well being Destination fitness Home care The road to independence Roadmap for managing pain Navigating the emergency department Bon Voyage Travelling with a bleeding disorder Charting Your Course PEP Parents Empowering Parents program Vocational assessment tool Career planning and scholarship links Scholarship Program Federal and Provincial Support Programs Insurance coverage Educational Material Printed documents Bleeding disorders in women Carriers of hemophilia A or B Hemophilia Hepatitis C HIV Inhibitors Physical activity and sports Platelet function disorders Rare factor deficiencies Relevant to all bleeding disorders Resources for children Von Willebrand disease Videos Care and Treatment Emergency Care Pain Management Nursing Physiotherapy Introduction Constitution of the Canadian Physiotherapists in Hemophilia Care CPHC Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded

    Original URL path: http://www.hemophilia.ca/en/research/the-chs---pfizer-care-until-cure-research-program/ (2014-10-09)
    Open archived version from archive

  • General Criteria - Canadian Hemophilia Society
    to well being Destination fitness Home care The road to independence Roadmap for managing pain Navigating the emergency department Bon Voyage Travelling with a bleeding disorder Charting Your Course PEP Parents Empowering Parents program Vocational assessment tool Career planning and scholarship links Scholarship Program Federal and Provincial Support Programs Insurance coverage Educational Material Printed documents Bleeding disorders in women Carriers of hemophilia A or B Hemophilia Hepatitis C HIV Inhibitors Physical activity and sports Platelet function disorders Rare factor deficiencies Relevant to all bleeding disorders Resources for children Von Willebrand disease Videos Care and Treatment Emergency Care Pain Management Nursing Physiotherapy Introduction Constitution of the Canadian Physiotherapists in Hemophilia Care CPHC Standards of Physiotherapy Care and Assessment Selected Journal Articles Educational material Bibliography Other resources Social Work Community Partners and Links Practice Guidelines Mission Services Interventions Standards of Practice Comprehensive Care Standards Safe Secure Blood Supply Products in the pipeline CHS Policy on Paid Plasma Donations Report Cards on Canada s Blood System 2008 2010 Report Card on Canada s Blood System 2005 2007 Report Card on Canada s Blood System 2003 2004 Report Card on Canada s Blood System 2002 Report Card on Canada s Blood System 1999 Report Card on Canada s Blood System Inhibitor rates related to treatment product in previously untreated patients Statement from the WFH variant Creutzfeldt Jakob disease vCJD CHS position on donor deferrals CHS position on HIV O deferral in Africa Hemophilia Research Million Dollar Club Research CHS Dream of a Cure Research Program General Criteria General Conditions Application Forms Summer Studentships in Inherited Bleeding Disorders Research CHS Research Grants for 2014 CHS Research Grants for 2013 CHS Research Grants for 2012 CHS Research Grants for 2011 CHS Research Grants for 2010 CHS Research Grants for 2009 CHS Research Grants for 2008 CHS Research Grants for 2007 CHS Research Grants for 2006 CHS Research Grants for 2005 The CHS Pfizer Care Until Cure Research Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Projects Funded in 2013 Research Projects Funded in 2012 Research Projects Funded in 2011 Research Projects Funded in 2010 Research Projects Funded in 2009 Research Projects Funded in 2008 Research Projects Funded in 2007 Research Projects Funded in 2006 Research Projects Funded in 2005 CHS Novo Nordisk Psychosocial Research Program General Criteria General Conditions Application form Research Project Funded in 2014 Hemostasis Fellowship Program General Criteria General Conditions Application form Research Project Funded in 2014 Research Project Funded in 2013 Research Project Funded in 2012 Research Project Funded in 2011 Research Project Funded in 2010 Research Project Funded in 2009 Research Project Funded in 2008 Research Project Funded in 2007 Research Project Funded in 2006 Research Project Funded in 2005 CHS Baxter Fellowship Program General Criteria General Conditions Application Form Research Projects Funded in 2014 Research Project Funded in 2013 Opportunities to participate in research Opportunities to participate in marketing research studies International Development Karttik Shah Youth Fellowship International Twinning Projects Canadian Centre Twins Hemophilia Treatment

    Original URL path: http://www.hemophilia.ca/en/research/the-chs---pfizer-care-until-cure-research-program/general-criteria/ (2014-10-09)
    Open archived version from archive

  • General Conditions - Canadian Hemophilia Society
    survivor HCV treatment support for 1986 1990 claimants National Endowment Fund Scholarship University of Ottawa Criminalization of HIV Non Disclosure HIV Know your rights US travel ban lifted World Hepatitis Day Recommendations for a Canadian Hepatitis C Strategy 2005 Hepatitis C An information booklet Alternative therapies Diagnosis Final Thoughts Getting treatment Healthy Lifestyle Hepatitis C Introduction Hepatitis C and HIV Co infection Psychosocial Aspects Standards of Care Symptoms Treatment Options for Hepatitis C Liver transplantation Youth Web About Us News Feed To Contact Us Commemoration of the Tainted Blood Tragedy Tree of Life Commemorations Canadian Blood Services November 26 2007 Héma Québec October 9 2008 CHS Newfounland Labrador Chapter Commemoration 2008 2009 Hemophilia Saskatchewan Commemoration 2009 CHS British Columbia Chapter Commemoration 2009 CHS Prince Edward Island Chapter Commemoration 2009 Hemophilia Ontario Commemoration 2009 Hemophilia Ontario Commemoration 2010 CHS Manitoba Chapter Commemoration 2010 Hemophilia Ontario Commemoration 2011 New Brunswick Chapter Commemoration 2012 Hemophilia Ontario Commemoration 2012 Hemophilia Saskatchewan Commemoration 2012 Hemophilia Saskatchewan Commemoration 2103 Hemophilia Ontario Commemoration 2013 Hemophilia Alberta Commemoration 2014 Media Room Press releases 2009 2011 Press releases 2006 2008 Search Français Our Partners General Conditions 1 General Conditions 2 Additional Grant Conditions and Grantee Obligations 3 Ethical considerations 1 General Conditions 1 1 Application Forms The Application Form may be obtained by clicking on the following link Application Form Applications forms must be completed and submitted electronically to the Canadian Hemophilia Society chs hemophilia ca and one 1 original paper copy including signatures must be sent to the National Office of the Canadian Hemophilia Society 666 Sherbrooke Street West Suite 301 Montreal QC H3A 1E7 1 2 Application Deadline Completed application forms and supporting documents must arrive at the National Office of the Canadian Hemophilia Society by November 14 2014 If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date then it is considered to have been submitted on time The names of the successful applicants will be announced by March 2015 First time applicants are encouraged to seek advice from experienced investigators in the preparation of their applications Please note that the Research Proposal Item 17 of the application must not exceed 5000 words excluding figures and references Supporting materials should include only previously published articles or materials accepted for publication 1 3 Grant Year and Amount Individual grants valued at 75 000 per year and per project will be awarded to researchers for a maximum of 150 000 which can be expended over 2 or 3 years If a two year award is provided the second year of funding is dependent on evidence of progress as described in the required progress report Grant funding will begin on April 1 of each year 1 4 Grant Payments Yearly grants will normally be disbursed in two payments in each year and sent to the financial officer of the host institution 1 5 Research Summaries The Canadian Hemophilia Society CHS requires within the application form a 200 word typewritten lay description of the research to be undertaken in non scientific Grade 12 readability for inclusion in the Society s publications should the proposal be accepted 1 6 Notification of Grants Following funding decisions successful applicants will be sent official notification informing them of the type duration and amount of their grant A copy of the notification is sent to the accountant at the institution concerned The award must be acknowledged by returning an acceptance note within 15 days of the CHS notification otherwise the award will be withdrawn Unsuccessful applicants are also advised at the conclusion of the project application review process 1 7 Appeals The Research Peer Review Committee of the Canadian Hemophilia Society will make recommendations on the awarding of the grants and the final decision will be made by the CHS Board of Directors No appeals will be considered 2 Additional Grant Conditions and Grantee Obligations 2 1 Statement of Expenditures A statement of all expenditures for the grant signed by the candidate and the financial officer of each institution must be received at the CHS s offices within 2 months of the end date of the grant term An institution finance expenditure report is acceptable to avoid duplication of effort by the researcher Failure to fulfill this requirement may lead to exclusion from future research grant competitions If delay is anticipated the CHS must be informed 2 2 Changes in the Use of the Grant The use of funds for purposes other than stated in the application must be approved in advance by the CHS 2 3 Unexpended Balances The Canadian Hemophilia Society does not permit carrying forward into the next grant year an unexpected balance in excess of 5 000 Prior written request to the CHS is required to carry forward a balance that exceeds 5 000 2 4 Termination of the Grant Upon termination of the project any unexpended balance of funds must be returned to the CHS 2 5 Travel Expenses A grantee may use 1 500 annually from the award for the purpose of travel in connection with the grant and if needed an additional amount representing one percent 1 of the annual value of the award 2 6 Title to Equipment Title to any equipment obtained with the Canadian Hemophilia Society s funds shall be held by the host institution on the condition that for a 12 month period following termination of grant the CHS may transfer title to another institution Prior written authorization for the transfer of funds or equipment by a grantee to another institution must be obtained from the CHS 2 7 Interim Final Report Abstract Requirements Research grant recipients are required to provide a project progress report for each year of funding allocation This report will serve as the basis for review of the project and approval of second year funding where applicable The progress report will also provide supporting rationale if required for approval of project modifications and or extension requests Within 2 months of

    Original URL path: http://www.hemophilia.ca/en/research/the-chs---pfizer-care-until-cure-research-program/general-conditions/ (2014-10-09)
    Open archived version from archive